Mind Medicine (MindMed) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNMD research report →
Range $14 – $28
Price Chart
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials.
- CEO
- Robert Barrow
- IPO
- 2016
- Employees
- 74
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on MNMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.56B
- P/E
- -9.57
- Fwd P/E
- 22.09
- PEG
- 0.20
- P/S
- 0.00
- P/B
- 4.07
- EV/EBITDA
- -11.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.04%
- ROIC
- -25.25%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-166,309,000
- Net Income
- $-183,793,000-69.1%
- EPS
- $-2.06-33.8%
- OCF Growth
- -66.3%
- FCF Growth
- -66.3%
- 52W High
- $21.08
- 52W Low
- $4.70
- 50D MA
- $12.71
- 200D MA
- $9.85
- Beta
- 2.62
- RSI (14)
- 67
- Avg Volume
- 2.53M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Definium said Q3 marked an inflection point, with positive Phase 3 data in GAD and MDD, FDA breakthrough designations for DT120 ODT, and a cash runway into 2030 supporting an NDA filing targeted for the first half of 2027.· November 9, 2026
- DT120 ODT posted positive Phase 3 results across three studies in GAD and MDD, with rapid onset and durable effects through week 12.
- FDA granted DT120 ODT two breakthrough therapy designations, and management said it remains on track for an NDA filing in the first half of 2027.
- Cash, cash equivalents and investments were approximately $1.05 billion at 9/30/2026, and management said that funds planned operations into 2030.
- DT402 in ASD showed encouraging early signals in a very small study of five participants, supporting a planned multiday-dosing study in 2027.
- Commercial and medical affairs buildout is underway ahead of launch, including market access, distribution, patient services, and provider readiness work.
Cash, cash equivalents and investments were approximately $1.05 billion as of 9/30/2026, up from $412 million as of 12/31/2025. R&D expense was $46.1 million in Q3 2026 versus $31 million in Q3 2025, and G&A expense was $26.1 million versus $14.7 million in the prior-year quarter. Net loss was $51 million compared with $67.3 million a year ago. Management said current resources are expected to fund planned operations into 2030. On the clinical side, VOYAGE enrolled 214 participants and showed a 5.4 placebo-adjusted improvement on HAM-A at week 12 with p<0.0001 and Cohen's d of 0.81; PANORAMA enrolled 245 participants and showed a 5.1 placebo-adjusted HAM-A improvement at week 12 with p<0.0001 and Cohen's d of 0.64. EMERGE met its primary and all key secondary endpoints, but management did not restate a specific numeric effect size on the call. DT402’s open-label Phase 2a study enrolled five participants before being stopped for a sufficient early signal, and the company plans a 2027 study of multiday dosing. Forward guidance: the company expects an NDA filing in the first half of 2027, ASCEND top-line data in 2027, HAVEN initiation in 2027, and says DT402 next-stage work will begin in 2027.
Robert Barrow framed the quarter as an inflection point, emphasizing that the company now has strong Phase 3 validation, two breakthrough therapy designations for DT120, and a clearer path to a first-half-2027 NDA. He stressed that the company is not only preparing for filing, but also building the commercial, medical, and patient-support infrastructure needed for launch if approved. His tone was confident and upbeat, while still noting there is “important work ahead.”
Brandi Roberts highlighted a strong balance sheet, with about $1.05 billion in cash, cash equivalents and investments as of 9/30/2026 versus $412 million at year-end 2025, and said that cash is expected to fund operations into 2030. She walked through quarterly spending: R&D rose to $46.1 million from $31 million and G&A rose to $26.1 million from $14.7 million, reflecting personnel growth, DT120 development, commercial preparedness, and legal/patent costs. She said operating expenses were consistent with expectations and that spending moderated somewhat versus Q2 as the company moved through key clinical readouts.
Analysts focused on the regulatory path for DT120, including whether a pre-NDA meeting has occurred and how the company would communicate the outcome; management said it has ongoing constructive dialogue with FDA and typically shares details after meeting minutes are received. Several questions probed whether the company would alter filing strategy depending on other psychedelic filings or on ASCEND timing, and management repeatedly said it is focused on the most efficient path to market but would not get into specific filing details yet. On commercialization, management said the recent Usona filing does not change its pricing or launch strategy, and Matthew Wiley reiterated prior payer feedback suggesting a pricing corridor of roughly $30,000 to $75,000. Questions on PTSD and DT402 centered on study design and patient selection; management said PTSD is not expected to be harder than prior indications, the team plans to use CAPS-5 at week 8, and the DT402 stop after five patients was based on a predefined goal of stopping once a strong early signal was seen.
The call presented a rare combination of late-stage clinical success, regulatory momentum, and a very large cash cushion. Management sounded increasingly confident that DT120 could address major unmet needs in GAD and MDD, with a possible follow-on PTSD program and early DT402 signal broadening the pipeline. The company also said launch planning is well underway, which suggests it believes commercialization is becoming a real near-term possibility.
The main risks are still regulatory and execution-related: the company has not filed the NDA yet, still needs to get through the pre-NDA process, and ASCEND is ongoing with top-line data not expected until 2027. DT402 is extremely early, based on only five participants, and management explicitly said those findings should be viewed in that context. There is also uncertainty around launch timing, pricing, and how quickly clinicians and payers will adopt a supervised-treatment model if DT120 is approved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.2%
- Shares Outstanding
- 75.55M
- Float Shares
- 73.44M
of shares held by institutions
210 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.59M | ▲ 579.03K |
| Cubist Systematic Strategies, LLC | 108.21K | ▲ 108.21K |
| Two Sigma Advisers, LP | 65.28K | ▼ 16.20K |
| Wolverine Trading, LLC | 60.25K | ▲ 60.25K |
| Moloney Securities Asset Management, LLC | 23.51K | ▼ 8.00K |
| Avantax Advisory Services, Inc. | 11.14K | ▼ 459 |
| Point72 Asia (Singapore) Pte. Ltd. | 10.22K | ▲ 10.22K |
| Point72 (Difc) Ltd | 4.58K | ▲ 4.58K |
| Point72 Europe (London) Llp | 815 | ▲ 815 |
| Cibc Private Wealth Group LLC | 151 | 0 |
| Guerra Advisors Inc | 66 | ▲ 66 |
| Belmont Capital, LLC | 6 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 22 | Makes Brigid | other | 361,680 |
| Jun 1, 22 | Makes Brigid | other | 100,308 |
| Jun 1, 22 | Makes Brigid | other | 64,656 |
| May 23, 22 | Greenway Schond L. | other | 1,650,000 |
| May 23, 22 | Greenway Schond L. | other | 1,270,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MNMD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MNMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4%
defenseworld.net · Jan 21
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com · Jan 14
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock
defenseworld.net · Dec 30
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
zacks.com · Dec 29
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts
defenseworld.net · Dec 26
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com · Dec 18
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
zacks.com · Dec 16
MindMed Announces New Employee Inducement Grant
businesswire.com · Dec 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
